专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

111. 发明申请

US20140302096A1 COMPOSITIONS FOR THE PREPARATION OF MATURE DENDRITIC CELLS 有权
标题翻译：用于制备成熟细胞的组合物
公开(公告)号：US20140302096A1
公开(公告)日：2014-10-09
申请号：US14174064
申请日：2014-02-06
申请人： Helmholtz Zentrum Munchen Deutsches Forschungszentrum fur Gesundheit und Umwelt (GmbH)
发明人： Dolores J. SCHENDEL , Anke ZOBYWALSKI , Iris BIGALKE
IPC分类号： C12N5/0784 , C12N15/85 , A61K35/14 , A61K39/00
CPC分类号： C12N5/0639 , A61K35/15 , A61K39/0011 , A61K2035/124 , C12N15/85 , C12N2501/02 , C12N2501/23 , C12N2501/2301 , C12N2501/24 , C12N2501/25 , C12N2501/50 , C12N2501/999
摘要： The invention relates to a method for in vitro maturation of at least one immate dendritic cell, comprising stimulating said immature dendritic cell with TNFα, IL-1β, IFNγ, a TLR7/8 agonist and prostaglandin E2(PG). Furthermore, the invention elates to a composition comprising these factors as well as to mature dendritic cells produced by a method of the invention.
摘要翻译：本发明涉及一种用于体外成熟至少一种死亡树突状细胞的方法，包括用TNFα，IL-1和bgr;IFNγ，TLR7 / 8激动剂和前列腺素E2（PG）刺激所述未成熟树突状细胞。此外，本发明涉及包含这些因素的组合物以及通过本发明的方法产生的成熟树突状细胞。

112. 发明授权

US08785189B2 Method of forming dendritic cells from embryonic stem cells 有权
标题翻译：从胚胎干细胞形成树突状细胞的方法
公开(公告)号：US08785189B2
公开(公告)日：2014-07-22
申请号：US13859228
申请日：2013-04-09
申请人： Wisconsin Alumni Research Foundation
发明人： Igor I. Slukvin , James A. Thomson , Maksym A. Vodyanyk , Maryna E. Gumenyuk
IPC分类号： C12N5/071 , C12N5/00 , C12N5/02 , C12N5/0784
CPC分类号： C12N5/0639 , C12N5/064 , C12N2506/02
摘要： This invention relates to the culture of dendritic cells from human embryonic stem (ES) cells. Human ES cells are first cultured into hematopoietic cells by co-culture with stromal cells. The cells now differentiated into the hematopoietic lineage are then cultured with GM-CSF to create a culture of myeloid precursor cells. Culture of the myeloid precursor cells with the cytokines GM-CSF and IL-4 causes functional dendritic cells to be generated. The dendritic cells have a unique phenotype, as indicated by their combination of cell surface markers.
摘要翻译：本发明涉及来自人胚胎干（ES）细胞的树突状细胞的培养。首先通过与基质细胞共培养将人类ES细胞培养成造血细胞。然后将分化成造血谱系的细胞与GM-CSF一起培养以产生骨髓前体细胞的培养物。用细胞因子GM-CSF和IL-4培养骨髓前体细胞会导致产生功能性树突状细胞。树突细胞具有独特的表型，如细胞表面标志物的组合所示。

113. 发明授权

US08741642B2 Methods for producing autologous immune cells resistant to myeloid-derived suppressor cells effects 有权
标题翻译：用于产生对骨髓来源的抑制细胞有抗性的自体免疫细胞的方法
公开(公告)号：US08741642B2
公开(公告)日：2014-06-03
申请号：US13877536
申请日：2011-10-21
申请人： Masoud H. Manjili , Harry D. Bear , Maciej Kmieciak
发明人： Masoud H. Manjili , Harry D. Bear , Maciej Kmieciak
IPC分类号： C12N5/0783 , C12N5/0784 , A61P35/00
CPC分类号： C12N5/0646 , A61K35/15 , A61K35/17 , A61K2039/5158 , C12N5/0634 , C12N5/0636 , C12N5/0639 , C12N2501/2302 , C12N2501/2307 , C12N2501/2315 , C12N2501/999
摘要： Methods for the ex vivo generation of cells of the innate (NKT cells and NK cells) and adaptive (T cells) immune systems for use in adoptive cell transfer (ACT) are provided. The NKT cells render T cells resistant to immune suppression (e.g. they are resistant to the effects of myeloid-derived suppressor cells (MDSCs)). The method involves culturing disease-primed immune cells (obtained from a cancer patient or from a patient with an infectious disease) with i) bryostatin and ionomycin (B/I) to activate and differentiate the cells; followed by sequentially culturing the cells with a) a combination of IL-7 and IL-15 and then b) IL-2, to further differentiate the cells and to render them immune resistant. The resistant immune cells are used to treat and prevent cancer and infectious diseases.
摘要翻译：提供了用于过继细胞转移（ACT）的先天（NKT细胞和NK细胞）和适应性（T细胞）免疫系统的细胞的体外产生的方法。 NKT细胞使T细胞对免疫抑制有抗性（例如，它们对骨髓来源的抑制细胞（MDSC）的作用具有抗性）。该方法包括用i）苔藓抑制素和离子霉素（B / I）培养疾病引发的免疫细胞（从癌症患者或患有感染性疾病的患者获得）以激活和分化细胞; 随后用a）IL-7和IL-15的组合，然后b）IL-2依次培养细胞，以进一步区分细胞并使其免疫抗性。抗性免疫细胞用于治疗和预防癌症和传染病。

114. 发明授权

US08741639B2 Method for producing dendritic cells 有权
标题翻译：树突状细胞的制备方法
公开(公告)号：US08741639B2
公开(公告)日：2014-06-03
申请号：US13127753
申请日：2009-11-13
申请人： Yoshikazu Yonemitsu , Yasuji Ueda , Yui Harada
发明人： Yoshikazu Yonemitsu , Yasuji Ueda , Yui Harada
IPC分类号： A61K39/00 , C12N5/0784
CPC分类号： C12N5/0639 , A61K39/00 , C12N2501/125 , C12N2501/145 , C12N2501/22 , C12N2501/23 , C12N2501/26
摘要： An objective of the present invention is to provide methods for producing dendritic cells (DCs), which comprise the step of culturing DC precursor cells in the presence of a plurality of cytokines, produced dendritic cells, and uses thereof.The present inventors discovered that dendritic cells with a high IL-12 productivity can be obtained by culturing DC precursor cells in the presence of a plurality of cytokines, followed by about one week of culture in the presence of GM-CSF and IL-4. The present invention enables preparation of a large amount of DCs with a high IL-12 productivity from a small number of DC precursor cells, and therefore makes it easier to increase the number of DCs for administration in DC-based anti-tumor immune therapy, treatment of infections, etc. Thus, the effect of DC vaccines is expected to be enhanced.
摘要翻译：本发明的目的是提供用于制备树突状细胞（DC）的方法，其包括在多种细胞因子，产生的树突状细胞的存在下培养DC前体细胞的步骤及其应用。本发明人发现通过在多种细胞因子的存在下培养DC前体细胞，然后在GM-CSF和IL-4存在下培养约1周，可获得具有高IL-12生产能力的树突状细胞。本发明能够从少量的DC前体细胞制备大量具有高IL-12生产能力的DC，因此可以更容易地增加DC-抗肿瘤免疫治疗中用于给药的DC数量，治疗感染等。因此，预期DC疫苗的效果将得到提高。

115. 发明申请

US20140072596A1 EX VIVO, FAST AND EFFICIENT PROCESS TO OBTAIN ACTIVATED ANTIGEN-PRESENTING CELLS THAT ARE USEFUL FOR THERAPIES AGAINST CANCER AND IMMUNE SYSTEM-RELATED DISEASES 有权
标题翻译： EX VIVO，快速有效的方法来获得有效的抗癌药物和免疫系统相关疾病的活化抗原呈递细胞
公开(公告)号：US20140072596A1
公开(公告)日：2014-03-13
申请号：US13875119
申请日：2013-05-01
申请人： UNIVERSIDAD DE CHILE , ONCOBIOMED
发明人： Flavio Andres SALAZAR ONFRAY , Mercedes Natalia LOPEZ NITSCHE , Cristian Javier PEREDA RAMOS , Raquel Elvira AGUILERA INSUNZA , Alejandro Felipe ESCOBAR ALVAREZ
IPC分类号： A61K39/00 , C12N5/09 , C12N5/0784
CPC分类号： A61K39/0011 , A61K2035/124 , A61K2039/5154 , A61K2039/55511 , C12N5/0639 , C12N5/0693 , C12N2500/84 , C12N2501/02 , C12N2501/05 , C12N2501/056 , C12N2501/07 , C12N2501/22 , C12N2501/23 , C12N2501/24 , C12N2501/25 , C12N2506/11
摘要： The present invention relates to an ex vivo, fast and efficient process to obtain activated antigen-presenting cells that are useful for therapies against cancer and immune system-related diseases. At the same time, it is related to a cellular composition that contributes to stimulate the activated antigen-presenting cells to induce a specific immune response against tumors in patients with cancer or other pathologies involving immune responses.
摘要翻译：本发明涉及获得活化的抗原呈递细胞的离体，快速和有效的方法，其可用于治疗癌症和免疫系统相关疾病。同时，它涉及有助于刺激活化的抗原呈递细胞诱导癌症患者或涉及免疫应答的其它病症的肿瘤的特异性免疫应答的细胞组合物。

116. 发明申请

US20140056845A1 Method for Generating Potent Dendritic Cells 有权
标题翻译：产生强效树突细胞的方法
公开(公告)号：US20140056845A1
公开(公告)日：2014-02-27
申请号：US14111479
申请日：2012-04-16
申请人： Robert Lazarus Modlin , Mirjam Schenk
发明人： Robert Lazarus Modlin , Mirjam Schenk
IPC分类号： C12N5/0784 , A61K38/20 , A61K39/39 , A61K35/14
CPC分类号： C12N5/0639 , A61K35/15 , A61K38/20 , A61K39/00 , A61K39/39 , A61K2039/5154 , C12N2501/2332
摘要： Highly potent dendritic cells are generated in vivo or ex vivo by exposing precursor cells to an effective dose of IL-32.
摘要翻译：通过将前体细胞暴露于有效剂量的IL-32，在体内或离体产生高效树突状细胞。

117. 发明授权

US08628762B2 T-helper cell type 17 lineage-specific adjuvants, compositions and methods 有权
标题翻译： T辅助细胞17型谱系特异性佐剂，组合物和方法
公开(公告)号：US08628762B2
公开(公告)日：2014-01-14
申请号：US13133817
申请日：2009-12-09
申请人： Julie Magarian Blander , Miriam Torchinsky
发明人： Julie Magarian Blander , Miriam Torchinsky
IPC分类号： C12N5/0784 , C12N1/00
CPC分类号： A61K39/39 , A61K39/0011 , A61K39/39533 , A61K2039/5154 , A61K2039/5156 , A61K2039/57
摘要： The present invention relates to compositions and methods for the modulation of TN 17 responses. The invention provides compositions for the induction of TN 17 responses containing a TLR agonist and an apoptotic cell-associated agent or containing a microbe-infected apoptotic cell. The compositions of the present invention may also contain dendritic cells capable inducing TN 17 responses. In other embodiments, the invention provides compositions for the inhibition of TN 17 responses containing one or more blocking agents. Methods and compositions for the modulation of TN 17 responses and for the treatment of TN 17-associated diseases and for cancer are also provided.
摘要翻译：本发明涉及用于调节TN17应答的组合物和方法。本发明提供用于诱导含有TLR激动剂和凋亡细胞相关药物或含有微生物感染的凋亡细胞的TN17应答的组合物。本发明的组合物还可含有能诱导TN17应答的树突状细胞。在其它实施方案中，本发明提供了用于抑制含有一种或多种封闭剂的TN17应答的组合物。还提供了用于调节TN17应答和治疗TN17相关疾病和癌症的方法和组合物。

118. 发明授权

US08609410B2 Method for activation treatment of antigen-presenting cell 有权
标题翻译：抗原呈递细胞的活化治疗方法
公开(公告)号：US08609410B2
公开(公告)日：2013-12-17
申请号：US12066313
申请日：2006-09-05
申请人： Mie Nieda , Manami Isogai , Masashi Takahara , Andrew Nicol
发明人： Mie Nieda , Manami Isogai , Masashi Takahara , Andrew Nicol
IPC分类号： C12N5/078 , C12N5/0784
CPC分类号： C12N5/0639 , A61K38/00 , A61K39/0011 , A61K2039/5158 , C12N5/0636
摘要： Activated antigen-presenting cells that can induce immunocytes including disease antigen-specific CD8+ CTLs and/or γδ T cells efficiently in vivo and/or in vitro, a medical composition comprising the activated antigen-presenting cells, a treatment and prevention method using the activated antigen-presenting cells, and an induction method of immunocytes including disease antigen-specific CTLs and/or γδ T cells induced using the activated antigen-presenting cell, immunocytes induced by the above-noted method, a medical composition comprising the immunocytes, and a treatment and prevention method using the immunocytes are provided. By co-pulsing antigen-presenting cells with bisphosphonate in addition to the pulse with a disease antigen, the ratio of disease antigen-specific CD8+ CTLs and/or γδ T cells and the number of the disease antigen-specific CD8+ CTLs and the γδ T cells can be increased, compared with the case where the co-pulse with bisphosphonate is not carried out.
摘要翻译：可在体内和/或体外有效诱导包括疾病抗原特异性CD8 + CTL和/或Gammadelta T细胞的免疫细胞的活化抗原呈递细胞，包含活化的抗原呈递细胞的药物组合物，使用活化的抗原呈递细胞的治疗和预防方法抗原呈递细胞，以及包括使用活化的抗原呈递细胞诱导的疾病抗原特异性CTL和/或Gammadelta T细胞的免疫细胞的诱导方法，由上述方法诱导的免疫细胞，包含免疫细胞的药物组合物和提供了使用免疫细胞的治疗和预防方法。除具有疾病抗原的脉冲之外，通过将抗原呈递细胞与双膦酸盐共脉冲，疾病抗原特异性CD8 + CTL和/或Gammadelta T细胞的比例以及疾病抗原特异性CD8 + CTL和gammadelta T的数量与不进行与双膦酸盐的共脉冲的情况相比，可以增加细胞。

119. 发明申请

US20130295120A1 VACCINES BASED ON TARGETING ANTIGEN TO DCIR EXPRESSED ON ANTIGEN-PRESENTING CELLS 有权
标题翻译：基于抗原向抗原呈递细胞表达的DCIR的抗生素疫苗
公开(公告)号：US20130295120A1
公开(公告)日：2013-11-07
申请号：US13872793
申请日：2013-04-29
申请人： Baylor Research Institute
发明人： Gerard Zurawski , Jacques F. Banchereau , Eynav Klechevsky , Sandra Zurawski , Anne-Laure Flamar
IPC分类号： C07K16/28 , C12N5/0784
CPC分类号： C07K16/2851 , A61K39/02 , A61K39/12 , A61K39/145 , A61K39/21 , A61K47/6897 , A61K47/6901 , A61K2039/505 , A61K2039/6056 , B82Y5/00 , C12N5/0639 , C12N2760/16134
摘要： The present invention includes compositions and methods for increasing the effectiveness of antigen presentation using a DCIR-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex.
摘要翻译：本发明包括使用形成抗体 - 抗原复合物的抗原附着的DCIR特异性抗体或其片段增加抗原呈递的有效性的组合物和方法，其中所述抗原由具有抗体 - 抗原复合物的树突状细胞加工和呈递，与抗体 - 抗原复合物接触。

120. 发明申请

US20130243724A1 COMPOSITIONS AND METHODS FOR INDUCING MIGRATION BY DENDRITIC CELLS AND AN IMMUNE RESPONSE 有权
标题翻译：用于诱导细胞迁移的组合物和方法以及免疫应答
公开(公告)号：US20130243724A1
公开(公告)日：2013-09-19
申请号：US13825078
申请日：2011-09-19
申请人： Geoffrey William Stone
发明人： Geoffrey William Stone
IPC分类号： C12N5/0784 , A61K39/245 , A61K39/00 , C12N15/85
CPC分类号： C12N5/0639 , A61K35/15 , A61K38/162 , A61K38/191 , A61K38/2006 , A61K38/204 , A61K39/0011 , A61K39/245 , A61K39/39 , A61K45/06 , A61K2039/5154 , A61K2039/5156 , A61K2039/55511 , C07K14/005 , C07K14/70578 , C12N15/85 , C12N2510/00 , C12N2710/10043 , C12N2710/10071 , C12N2710/16244 , A61K2300/00
摘要： Compositions and methods of activating dendritic cells with LMP1 and LMP1-activated dendritic cell based compositions and methods are effective for dendritic cell therapy and provide an adjuvant function for vaccine administration. LMP1 or LMP1-CD40 chimeric protein may be used to activate and mature dendritic cells. LMP1 and LMP1-activated dendritic cells act as an adjuvant to enhance the cellular immune response. Also disclosed herein are kits for activating dendritic cells and for preparing a vaccine formulation. Administration of the dendritic cells transfected with LMP1 can induce an immune response against cancer or infection. The mature dendritic cells may comprise an antigen and at least one cytokine in addition to LMP1. Use of LMP1 or LMP1-CD40 provides a way to activate and mature dendritic cells that retain functional and migratory abilities without the side effects that result from maturing the dendritic cells using PGE2
摘要翻译：用LMP1和LMP1激活的树突状细胞的组合物和方法激活树突状细胞的组合物和方法对树突细胞治疗是有效的，并且为疫苗施用提供佐剂功能。 LMP1或LMP1-CD40嵌合蛋白可用于激活和成熟树突状细胞。 LMP1和LMP1激活的树突状细胞作为佐剂以增强细胞免疫应答。本文还公开了用于激活树突状细胞和制备疫苗制剂的试剂盒。用LMP1转染的树突状细胞的施用可以诱导针对癌症或感染的免疫应答。除了LMP1之外，成熟树突细胞可以包含抗原和至少一种细胞因子。使用LMP1或LMP1-CD40提供了激活和成熟树突状细胞的方式，保留了功能和迁移能力，而没有使用PGE2成熟树突状细胞所产生的副作用

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式